Purdue Frederick Company Profile

What is the competitive landscape for PURDUE FREDERICK

PURDUE FREDERICK has one approved drug.

Summary for Purdue Frederick

US Patents:	0
Tradenames:	1
Ingredients:	1
NDAs:	1

Drugs and US Patents for Purdue Frederick

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Purdue Frederick	SULFABID	sulfaphenazole	TABLET;ORAL	013092-002	Approved Prior to Jan 1, 1982		DISCN	No	No

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Purdue Frederick
• Purdue Pharma
• Purdue Pharma Lp

Purdue Frederick: Market Position, Strengths & Strategic Insights

Last updated: March 22, 2026

Purdue Frederick, a subsidiary of Purdue Pharma, is a key player in the pharmaceutical industry, primarily focused on pain management medications. The company's portfolio includes branded opioids and other pain therapies that have historically generated significant revenue. Purdue's market strategy revolves around product innovation, regulatory navigation, and addressing ongoing legal and ethical challenges.

What Is Purdue Frederick’s Current Market Position?

Purdue Frederick historically ranks among the top producers of opioid medications in the United States. Its flagship product, OxyContin (oxycodone ER), accounted for approximately 80% of the company's revenue prior to 2019, with estimates reaching over $3 billion annually. Following the 2019 bankruptcy filing and settlement agreements, Purdue’s market standing has shifted. The company’s influence remains, but legal and regulatory actions have diminished its market dominance.

Market share and revenue context (pre-2020):

• OxyContin: ~$3 billion annually
• Total revenue (2018): ~$3.2 billion
• Market share (opioids): Estimated 40-50% of the US prescription opioid market

Recent legal restrictions and decline in prescriptions have reduced Purdue’s market footprint. However, the company's focus on developing abuse-deterrent formulations and expanding into other pain management products continues to sustain its industry relevance.

What Are Purdue Frederick’s Core Strengths?

1. Product Portfolio:
   Purdue’s primary strength lies in its opioid product line, especially OxyContin, which became a dominant brand with a recognized market presence. Its formulations include extended-release and abuse-deterrent options, which appeal to clinicians seeking safer pain management solutions.

2. Research and Development (R&D):
   Purdue invests significantly in R&D to develop formulations that address abuse concerns and meet regulatory standards. Its early focus on abuse-deterrent technology influenced the market trend, prompting competitors to innovate similarly.

3. Brand Recognition and Distribution Network:
   Despite legal challenges, Purdue’s distribution channels are extensive, enabling rapid deployment of new formulations and maintaining relationships with hospitals, clinics, and pharmacies nationally.

4. Strategic Partnerships:
   Purdue has engaged with third-party researchers and institutions to enhance its R&D capacity and explore alternative pain therapies, including non-opioid options.

What Are Purdue Frederick’s Strategic Challenges?

1. Legal and Regulatory Risks:
   Purdue faces ongoing lawsuits related to the opioid epidemic, resulting in substantial financial liabilities and reputational damage. The 2019 bankruptcy filing transferred many liabilities to a trust but constrained future profits.

2. Market Decline in Opioid Prescriptions:
   Increased regulation, public awareness, and legislative measures have decreased opioid prescriptions by approximately 60% nationwide since 2015. This contraction limits growth opportunities.

3. Shift Toward Non-Opioid Pain Treatments:
   The medical community increasingly favors non-addictive pain management options, reducing reliance on opioids. Purdue must diversify its product pipeline accordingly.

4. Public Perception and Ethical Concerns:
   The company's association with opioid misuse results in stigma that affects marketing and adoption of its products.

What Strategic Initiatives Is Purdue Frederick Implementing?

• Diversification into Non-Opioid Pain Therapies:
  Purdue is exploring alternatives such as nerve regeneration, anti-inflammatory drugs, and biologics. Its partnerships with biotech firms support this shift.

• Emphasis on Abuse-Deterrent Formulations:
  Ramping up development of formulations resistant to crushing, dissolution, or injection aims to reduce misuse and comply with regulatory urges.

• Litigation Management and Settlement Strategies:
  Post-2019, Purdue focuses on negotiated settlements, creating a pathway to financial stability without public litigation disruptions.

• Focus on International Markets:
  Expansion into Europe and emerging markets offers growth potential, although regulatory landscapes differ.

How Does Purdue Frederick Compare with Competitors?

Company	Key Products	Market Share (Pre-2020)	Strategic Focus
Johnson & Johnson	Duragesic, Nucynta	~10% of opioid market	Diversification, non-opioids
Teva Pharmaceuticals	Kadian, Avinza	Approx. 8%	Generic opioids, biosimilars
Mallinckrodt	Exalgo, Ryzolt	Approx. 7%	Pain management, generics
Purdue Pharma (Purdue Frederick)	OxyContin, reformulations	40-50% (pre-2019)	Abuse deterrence, diversification

Purdue's historical dominance in the opioid sphere exceeds that of large peers, but regulatory and market shifts have caused declines.

What Are Future Outlooks for Purdue Frederick?

• Regulatory Environment:
  Federal and state regulations are likely to become stricter, emphasizing abuse deterrence and prescribing limits. Purdue must innovate within tighter frameworks.

• Market Dynamics:
  With the decreasing prescription rates of opioids, Purdue must expand into alternative pain therapies to sustain revenue growth.

• Legal Settlements and Financial Stability:
  Ongoing litigation will influence cash flow, balancing between settlement payments and R&D investment.

• Global Expansion:
  Emerging markets represent growth avenues, contingent on local regulatory alignment and intellectual property protections.

Key Takeaways

• Purdue Frederick holds a dominant position in the US opioid market historically but faces decline due to legal, regulatory, and societal pressures.
• Core strengths include a strong product portfolio, extensive distribution, and proactive R&D in abuse-deterrent formulations.
• Challenges include ongoing litigation liabilities, decreased opioid prescribing, and a shift toward non-addictive pain treatments.
• Strategic shifts focus on diversifying pain management products and expanding abroad.
• Competition emphasizes diversified portfolios, with Purdue's market share decreasing from its peak pre-2019.

FAQs

1. What is Purdue Frederick’s main product and its significance?
   OxyContin is Purdue’s flagship product, historically generating around $3 billion annually and constituting a significant portion of North American opioid sales.

2. How has legal action affected Purdue’s market position?
   Lawsuits and bankruptcy filings have diminished Purdue’s influence, transferred liabilities to a trust, and curtailed revenue streams.

3. What are Purdue Frederick’s growth prospects?
   Expansion into non-opioid therapies and international markets offers future growth, but success depends on regulatory adaptation and product innovation.

4. Are Purdue’s abuse-deterrent formulations effective?
   They have reduced some forms of misuse but have not eliminated abuse entirely. Their development reflects industry effort to meet regulatory and safety standards.

5. What recent strategies has Purdue implemented to address market shifts?
   The company pursues diversification into non-opioid pain treatments, strengthens R&D into abuse-deterrent drugs, and explores international opportunities.

---

Citations

1. U.S. Food and Drug Administration. (2019). OxyContin REMS (Risk Evaluation and Mitigation Strategies).
2. Purdue Pharma Bankruptcy Filing. (2019). United States Bankruptcy Court.
3. Johnson & Johnson Annual Report. (2021).
4. Teva Pharmaceuticals Annual Report. (2020).
5. MarketWatch. (2022). Opioid Market Share Analysis.